Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 2, 2022

Primary Completion Date

December 6, 2023

Study Completion Date

December 31, 2027

Conditions

Inherited Retinal Dystrophy Associated With RPE65 Mutations

Interventions

GENETIC

LX101

Subretinal Administration

Trial Locations (2)

Beijing Tongren Hospital, Capital Medical University, Beijing

Shanghai General Hospital, Shanghai